Philip Mazzara Sells 10,000 Shares of Astera Labs (NASDAQ:ALAB) Stock

Astera Labs, Inc. (NASDAQ:ALABGet Free Report) General Counsel Philip Mazzara sold 10,000 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $117.47, for a total transaction of $1,174,700.00. Following the sale, the general counsel owned 128,084 shares in the company, valued at $15,046,027.48. This trade represents a 7.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Philip Mazzara also recently made the following trade(s):

  • On Tuesday, February 17th, Philip Mazzara sold 4,849 shares of Astera Labs stock. The shares were sold at an average price of $123.80, for a total transaction of $600,306.20.

Astera Labs Stock Up 5.5%

Shares of ALAB opened at $120.00 on Friday. The company has a market cap of $20.43 billion, a P/E ratio of 98.36, a PEG ratio of 2.24 and a beta of 1.74. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The firm’s 50 day moving average price is $153.84 and its 200 day moving average price is $170.53.

Astera Labs (NASDAQ:ALABGet Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $270.58 million during the quarter, compared to analysts’ expectations of $249.46 million. During the same quarter last year, the company posted $0.37 EPS. The firm’s revenue was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Institutional Trading of Astera Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALAB. Vanguard Group Inc. grew its position in shares of Astera Labs by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 13,827,506 shares of the company’s stock valued at $2,300,344,000 after buying an additional 84,365 shares during the last quarter. State Street Corp boosted its stake in Astera Labs by 32.5% in the fourth quarter. State Street Corp now owns 3,099,809 shares of the company’s stock valued at $515,684,000 after acquiring an additional 760,358 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Astera Labs by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 2,429,078 shares of the company’s stock worth $403,598,000 after purchasing an additional 104,935 shares during the last quarter. Fred Alger Management LLC increased its position in shares of Astera Labs by 25.5% during the fourth quarter. Fred Alger Management LLC now owns 1,934,688 shares of the company’s stock worth $321,855,000 after purchasing an additional 393,250 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Astera Labs by 33.0% in the 4th quarter. Morgan Stanley now owns 1,934,467 shares of the company’s stock valued at $321,818,000 after purchasing an additional 480,009 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs News Summary

Here are the key news stories impacting Astera Labs this week:

  • Positive Sentiment: Loop Capital initiated coverage with a “Buy” and a $250 price target (roughly +100% upside vs. current levels), which can attract new buy-side interest and help lift sentiment. Benzinga
  • Positive Sentiment: Recent quarterly results showed an EPS and revenue beat plus strong year-over-year revenue growth and positive guidance (Q1 EPS guide provided), supporting a fundamental growth story for the company and giving investors confidence in near-term execution. MarketBeat ALAB
  • Positive Sentiment: Multiple sell-side firms have raised targets or maintain Buy/Outperform ratings (JPMorgan, Stifel, Northland, BNP Paribas Exane), and the consensus price target remains well above current trading levels—fuel for momentum traders and longer-term buyers. MarketBeat ALAB
  • Neutral Sentiment: Media pieces are debating valuation and whether the stock is “too late” after strong 1‑year gains; these articles can drive retail interest but are mixed in directional impact. Yahoo Finance InsiderMonkey
  • Neutral Sentiment: Reported short-interest figures in the feeds show contradictory/erroneous data (zeros and NaN values), so current short-interest signals are unreliable; treat these entries cautiously until corrected data is posted.
  • Negative Sentiment: Insider selling: General Counsel Philip Mazzara sold 10,000 shares at about $117.47 (disclosed via SEC Form 4), reducing his ownership. Insider sales can be perceived negatively by some investors even if routine or for diversification/liquidity reasons. SEC Form 4

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Loop Capital assumed coverage on Astera Labs in a research note on Thursday. They issued a “buy” rating and a $250.00 price objective for the company. Citigroup reduced their target price on shares of Astera Labs from $275.00 to $250.00 and set a “buy” rating on the stock in a report on Wednesday, February 11th. Barclays set a $165.00 price target on shares of Astera Labs in a research note on Thursday, January 15th. Jefferies Financial Group reissued a “buy” rating on shares of Astera Labs in a research report on Wednesday, December 3rd. Finally, Weiss Ratings lowered shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 23rd. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Astera Labs currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.89.

Read Our Latest Research Report on Astera Labs

About Astera Labs

(Get Free Report)

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

Further Reading

Insider Buying and Selling by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.